Company Registration No. 11501644 (England and Wales)
HRS Pharma Ltd
Unaudited accounts
for the year ended 31 August 2025
HRS Pharma Ltd
Statement of financial position
as at 31 August 2025
Tangible assets
12,150
7,500
Cash at bank and in hand
10,820
8,561
Creditors: amounts falling due within one year
(11,398)
(3,661)
Net current assets
670
4,900
Called up share capital
10
10
Profit and loss account
12,810
12,390
Shareholders' funds
12,820
12,400
For the year ending 31 August 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
The members have agreed to the preparation of abridged accounts for the year in accordance with Section 444(2A).
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board and authorised for issue on 3 November 2025 and were signed on its behalf by
Habibur Rahman Shah
Director
Company Registration No. 11501644
HRS Pharma Ltd
Notes to the Accounts
for the year ended 31 August 2025
HRS Pharma Ltd is a private company, limited by shares, registered in England and Wales, registration number 11501644. The registered office is 21 Springfield Place, Bradford, BD1 3EZ, England.
2
Compliance with accounting standards
The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. There were no material departures from that standard.
The principal accounting policies adopted in the preparation of the financial statements are set out below and have remained unchanged from the previous year, and also have been consistently applied within the same accounts.
The accounts have been prepared under the historical cost convention as modified by the revaluation of certain fixed assets.
The accounts are presented in £ sterling.
Tangible fixed assets and depreciation
Tangible assets are included at cost less depreciation and impairment. Depreciation has been provided at the following rates in order to write off the assets over their estimated useful lives:
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. Turnover from the sale of goods is recognised when goods have been delivered to customers such that risks and rewards of ownership have transferred to them. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
4
Tangible fixed assets
Total
At 1 September 2024
10,000
HRS Pharma Ltd
Notes to the Accounts
for the year ended 31 August 2025
5
Average number of employees
During the year the average number of employees was 1 (2024: 1).